Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Methylprednisolone in Idiopathic Pulmonary Fibrosis: NCT04996303 Clinical Landscape Report 2026
16 October 2026
NCT04996303 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Saroglitazar in Fibrosis, Liver: NCT05011305 Clinical Landscape Report 2026
16 October 2026
NCT05011305 clinical landscape for Fibrosis, Liver: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Semaglutide (Novo Nordisk) in Metabolic Dysfunction Associated Steatohepatitis: NCT05016882 Clinical Landscape Report 2026
16 October 2026
NCT05016882 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Losartan Potassium in Myocardial fibrosis: NCT05012631 Clinical Landscape Report 2026
16 October 2026
NCT05012631 clinical landscape for Myocardial fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
ECC-0509 in Metabolic Dysfunction Associated Steatohepatitis: NCT05012423 Clinical Landscape Report 2026
16 October 2026
NCT05012423 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
AlloRx(Vitro Biopharma) in Idiopathic Pulmonary Fibrosis: NCT05016817 Clinical Landscape Report 2026
16 October 2026
NCT05016817 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
PMG-1015 in Idiopathic Pulmonary Fibrosis: NCT05022771 Clinical Landscape Report 2026
16 October 2026
NCT05022771 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Sodium Phenylbutyrate/Tauroursodeoxycholic Acid in Amyotrophic Lateral Sclerosis: NCT05021536 Clinical Landscape Report 2026
16 October 2026
NCT05021536 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Hydroxycarbamide in Hematologic Diseases: PACTR202108893981080 Clinical Landscape Report 2026
16 October 2026
PACTR202108893981080 clinical landscape for Hematologic Diseases: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Voxelotor in Anemia, Sickle Cell: NCT05018728 Clinical Landscape Report 2026
16 October 2026
NCT05018728 clinical landscape for Anemia, Sickle Cell: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pegozafermin in Metabolic Dysfunction Associated Steatohepatitis: NCT05022693 Clinical Landscape Report 2026
16 October 2026
NCT05022693 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Mitapivat in Hemoglobin SC Disease: NCT05031780 Clinical Landscape Report 2026
16 October 2026
NCT05031780 clinical landscape for Hemoglobin SC Disease: endpoints, sponsor, phase, geography, readouts, asset context and development white space.